



GOVERNMENT OF BERMUDA

Registry General

Patent Application Advertisements PATENT AND DESIGN ACT 1930

GOVERNMENT NOTICE NO.: 16

Notice is hereby given that person who has grounds of Opposition to the registration of any of the Patent Applications advertised herein according to the Invention claimed under the heading "Patent Applications advertised before Registration" may within two months from the date of this publication, lodge with the Registrar, Notice of Opposition in writing in duplicate accompanied by a fee of \$45 payable either by cheque made payable to the Accountant General, by cash or by Revenue Stamp obtainable at the Office of the Accountant General.

Please further note that Patent Applications filed in Bermuda for registration are shown with the Official Number accompanied by letters BM. Patent applications registered in the United Kingdom and filed in Bermuda are shown with the Official Number accompanied by the letters UK. Patent Applications registered in the European Union designating the United Kingdom and filed in Bermuda are shown with the Official Number accompanied by the letters EP.

PATENT APPLICATIONS ADVERTISED BEFORE REGISTRATION

Patent No. 814EP

Description: N4-HYDROXYCYTIDINE DERIVATIVE AND ANTI-VIRAL USES RELATED THERETO

On **14 January 2026**, **Emory University**, delivered to the Registry of Patents and Designs a signed written declaration of certain invention, whereof the said **Emory University**, claims to be the Inventor or Proprietor of an invention: **N4-HYDROXYCYTIDINE DERIVATIVE AND ANTI-VIRAL USES RELATED THERETO**, together with a specification particularly describing the nature of such invention and the manner in which the same is to be performed. The said **Emory University** further requests that its name be entered in the Register of Patents as the Proprietor of this Patent.

Address for Service: **Alexanders, Barristers & Attorneys, Belvedere Building, 69 Pitts Bay Road (Ground Floor), Pembroke HM 08, Bermuda.**

Patent No. 815EP

Description: PCSK9 ANTAGONIST COMPOUNDS

On **14 January 2026**, **Merck Sharp & Dohme LLC**, delivered to the Registry of Patents and Designs a signed written declaration of certain invention, whereof the said **Merck Sharp & Dohme LLC**, claims to be the Inventor or Proprietor of an invention: **PCSK9 ANTAGONIST COMPOUNDS** together with a specification particularly describing the nature of such invention and the manner in which the same is to be performed. The said **Merck Sharp & Dohme LLC**, further requests that its name be entered in the Register of Patents as the Proprietor of this Patent.

Address for Service: **Alexanders, Barristers & Attorneys, Belvedere Building, 69 Pitts Bay Road (Ground Floor), Pembroke HM 08, Bermuda.**

Patent No. 816EP

Description: CRYSTALLINE SOLID FORMS OF A BET INHIBITOR

On **7 April 2026**, **Incyte Corporation**, delivered to the Registry of Patents and Designs a signed written declaration of certain invention, whereof the said **Incyte Corporation** claims to be the Inventor or Proprietor of an invention **CRYSTALLINE SOLID FORMS OF A BET INHIBITOR** together with a specification particularly describing the nature of such invention and the manner in which the same is to be performed. The said **Incyte Corporation** further requests that its name be entered in the Register of Patents as the Proprietor of this Patent.

Address for Service: **Cox Hallett Wilkinson Limited, Cedar House, 3rd Floor 41 Cedar Avenue, Hamilton HM 12, Bermuda**

Patent No. 817EP

Description: THYROID HORMONE ANALOGS

On **17 April 2026**, **Madrigal Pharmaceuticals, Inc. and F. Hoffmann-La Roche Ltd.**, delivered to the Registry of Patents and Designs a signed written declaration of certain invention, whereof the said **Madrigal Pharmaceuticals, Inc. and F. Hoffmann-La Roche Ltd.**, claims to be the Inventor or Proprietor of an invention **THYROID HORMONE ANALOGS** together with a specification particularly describing the nature of such invention and the manner in which the same is to be performed. The said **Madrigal Pharmaceuticals, Inc. and F. Hoffmann-La Roche Ltd.**, further requests that its name be entered in the Register of Patents as the Proprietor of this Patent.

Address for Service: **Cox Hallett Wilkinson Limited, Cedar House, 3rd Floor 41 Cedar Avenue, Hamilton HM 12, Bermuda**

Patent No. 818EP

Description: OXAZOLIDINONE COMPOUND AND ITS USE THEREOF AS AN ANTIBACTERIAL AGENT

On **2 July 2026**, **Merck Sharp & Dohme LLC**, delivered to the Registry of Patents and Designs a signed written declaration of certain invention, whereof the said **Merck Sharp & Dohme LLC**, claims to be the Inventor or Proprietor of an invention **OXAZOLIDINONE COMPOUND AND ITS USE THEREOF AS AN ANTIBACTERIAL AGENT** together with a specification particularly describing the nature of such invention and the manner in which the same is to be performed. The said **Merck Sharp & Dohme LLC**, further requests that its name be entered in the Register of Patents as the Proprietor of this Patent.

Address for Service: **Cox Hallett Wilkinson Limited, Cedar House, 3rd Floor 41 Cedar Avenue, Hamilton HM 12, Bermuda**

Patent No. 819EP

Description: CEFTOLOZANE/TAZOBACTAM FOR TREATING INTRAPULMONARY INFECTIONS

On **10 August 2026**, **Merck Sharp & Dohme LLC**, delivered to the Registry of Patents and Designs a signed written declaration of certain invention, whereof the said **Merck Sharp & Dohme LLC**, claims to be the Inventor or Proprietor of an invention **CEFTOLOZANE/TAZOBACTAM FOR TREATING INTRAPULMONARY INFECTIONS** together with a specification particularly describing the nature of such invention and the manner in which the same is to be performed. The said **Merck Sharp & Dohme LLC**, further requests that its name be entered in the Register of Patents as the Proprietor of this Patent.

Address for Service: **Cox Hallett Wilkinson Limited, Cedar House, 3rd Floor 41 Cedar Avenue, Hamilton HM 12, Bermuda.**

Patent No. 820EP

Description: TRICYCLIC UREA COMPOUNDS AS JAK2 V617F INHIBITORS

On **25 August 2026**, **Incyte Corporation** to the Registry of Patents and Designs a signed written declaration of certain invention, whereof the said **Incyte Corporation** claims to be the Inventor or Proprietor of an invention **TRICYCLIC UREA COMPOUNDS AS JAK2 V617F INHIBITORS** together with a specification particularly describing the nature of such invention and the manner in which the same is to be performed. The said **Incyte Corporation**, further requests that its name be entered in the Register of Patents as the Proprietor of this Patent.

Address for Service: **Cox Hallett Wilkinson Limited, Cedar House, 3rd Floor 41 Cedar Avenue, Hamilton HM 12, Bermuda.**

Patent No. 821EP

Description: COMPOSITIONS COMPRISING STREPTOCOCCUS PNEUMONIAE POLYSACCHARIDE-PROTEIN CONJUGATES AND METHODS OF USE THEREOF

On **22 October 2026**, **Merck Sharp & Dohme LLC** delivered to the Registry of Patents and Designs a signed written declaration of certain invention, whereof the said **Merck Sharp & Dohme LLC**, claims to be the Inventor or Proprietor of an invention **COMPOSITIONS COMPRISING STREPTOCOCCUS PNEUMONIAE POLYSACCHARIDE-PROTEIN CONJUGATES AND METHODS OF USE THEREOF** together with a specification particularly describing the nature of such invention and the manner in which the same is to be performed. The said **Merck Sharp & Dohme LLC**, further requests that its name be entered in the Register of Patents as the Proprietor of this Patent.

Address for Service: **Cox Hallett Wilkinson Limited, Cedar House, 3rd Floor 41 Cedar Avenue, Hamilton HM 12, Bermuda.**